MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ
25.42
+0.07
+0.28%
After Hours: 25.42 0 0.00% 17:56 12/31 EST
OPEN
25.32
PREV CLOSE
25.35
HIGH
25.71
LOW
25.05
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
27.69
52 WEEK LOW
12.72
MARKET CAP
5.12B
P/E (TTM)
-8.9836
1D
5D
1M
3M
1Y
5Y
1D
Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares
Reuters · 12/30/2025 02:00
Weekly Report: what happened at IMVT last week (1222-1226)?
Weekly Report · 12/29/2025 09:22
How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution
Simply Wall St · 12/22/2025 19:16
Weekly Report: what happened at IMVT last week (1215-1219)?
Weekly Report · 12/22/2025 09:22
Immunovant (IMVT): Reassessing Valuation After a $550 Million Follow-On Equity Raise
Simply Wall St · 12/20/2025 18:14
Immunovant price target lowered to $41 from $44 at Guggenheim
TipRanks · 12/18/2025 13:36
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16/2025 14:19
Immunovant Is Maintained at Neutral by Goldman Sachs
Dow Jones · 12/15/2025 17:58
More
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Webull offers Immunovant Inc stock information, including NASDAQ: IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.